Literature DB >> 18609165

Small intestinal bacterial overgrowth.

S V Rana1, S B Bhardwaj.   

Abstract

Small intestinal bacterial overgrowth (SIBO) syndrome is characterized in its florid form by diarrhoea and weight loss. The most common underlying factors are dysmotility, small intestinal obstruction, blind or afferent loops. Small intestinal bacterial overgrowth can be diagnosed by: 1) culture of jejunum aspirate for bacterial counts, 2) 14C-D-xylose breath testing, 3) non-invasive hydrogen breath testing using glucose or lactulose or 4) 14C-glycocholic acid breath testing. The treatment usually consists of the eradication of bacterial overgrowth with repeated course of antimicrobials, correction of associated nutritional deficiencies and, when possible, correction of the underlying predisposing conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609165     DOI: 10.1080/00365520801947074

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  24 in total

1.  A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease.

Authors:  Matthew S Chang; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

2.  Endoscopic jejunal biopsy culture: a simple and effective method to study jejunal microflora.

Authors:  Sharad Chandra; Usha Dutta; Mohd Talha Noor; Neelam Taneja; Rakesh Kochhar; Meera Sharma; Kartar Singh
Journal:  Indian J Gastroenterol       Date:  2011-01-06

Review 3.  Management of afferent loop obstruction: Reoperation or endoscopic and percutaneous interventions?

Authors:  Konstantinos Blouhos; Konstantinos Andreas Boulas; Konstantinos Tsalis; Anestis Hatzigeorgiadis
Journal:  World J Gastrointest Surg       Date:  2015-09-27

4.  Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.

Authors:  Marjan Wouthuyzen-Bakker; Marcel J C Bijvelds; Hugo R de Jonge; Robert C De Lisle; Johannes G M Burgerhof; Henkjan J Verkade
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

5.  Evaluation and management of dyspepsia.

Authors:  R Christopher Harmon; David A Peura
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 6.  The mucosal firewalls against commensal intestinal microbes.

Authors:  Andrew J Macpherson; Emma Slack; Markus B Geuking; Kathy D McCoy
Journal:  Semin Immunopathol       Date:  2009-08-26       Impact factor: 9.623

Review 7.  Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.

Authors:  Alessandro Di Cerbo; Federica Pezzuto; Lucia Palmieri; Valentina Rottigni; Tommaso Iannitti; Beniamino Palmieri
Journal:  Int Urol Nephrol       Date:  2013-04-13       Impact factor: 2.370

8.  Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients.

Authors:  Richard A Schatz; Qing Zhang; Nilesh Lodhia; Jonathan Shuster; Phillip P Toskes; Baharak Moshiree
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Role of myosin light chain kinase in intestinal epithelial barrier defects in a rat model of bowel obstruction.

Authors:  Chi-Chin Wu; Yen-Zhen Lu; Li-Ling Wu; Linda C Yu
Journal:  BMC Gastroenterol       Date:  2010-04-20       Impact factor: 3.067

10.  Small intestinal mucosa expression of putative chaperone fls485.

Authors:  Andrea Reinartz; Josef Ehling; Susanne Franz; Verena Simon; Ignacio G Bravo; Claudia Tessmer; Hanswalter Zentgraf; Stefan Lyer; Ursula Schneider; Jan Köster; Kerstin Raupach; Elke Kämmerer; Christina Klaus; Jens J W Tischendorf; Jürgen Kopitz; Angel Alonso; Nikolaus Gassler
Journal:  BMC Gastroenterol       Date:  2010-03-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.